ULIPRISTAL ACETATE TABLETS

(ULIPRISTALI ACETATIS COMPRESSI)

Draft proposal for inclusion for The International Pharmacopoeia (July 2021)

DRAFT FOR COMMENTS

Please send any comments you may have on this draft working document to Dr Herbert Schmidt, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (schmidt@who.int), with a copy to Ms Sinéad Jones (jonessi@who.int) by 3 September 2021.

Our working documents are sent out electronically and they will also be placed on the WHO Medicines website (https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/current-projects) for comments under the “Working documents in public consultation” link. If you wish to receive our draft guidelines, please send your e-mail address to jonessi@who.int and your name will be added to our electronic mailing list.

© World Health Organization 2021

All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

Please send any request for permission to: Ms Sinéad Jones, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: jonessi@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.

However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/21.871:

ULIPRISTAL ACETATE TABLETS
(ULIPRISTALI ACETATIS COMPRESSI)

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monograph drafted based on information received from a manufacturer.</td>
<td>January 2021</td>
</tr>
<tr>
<td>Laboratory investigations to verify and validate the analytical provisions.</td>
<td>February – June 2021</td>
</tr>
<tr>
<td>Monograph sent out for public consultation.</td>
<td>July – August 2021</td>
</tr>
<tr>
<td>Further follow-up action as required.</td>
<td></td>
</tr>
</tbody>
</table>

[Note from the Secretariat. It is proposed to include a monograph on Ulipristal acetate tablets in The International Pharmacopoeia. The draft monograph is based on information provided by a manufacturer and on laboratory investigations.]
ULIPRISTAL ACETATE TABLETS
(ULIPRISTALI ACETATIS COMPRESSIONE)

Category. Oral hormonal contraceptive.

Storage. Ulipristal acetate tablets should be kept in a well-closed container, protected from light.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 30 mg Ulipristal acetate per tablet.

Requirements

The tablets comply with the monograph for Tablets.

Definition. Ulipristal acetate tablets contain Ulipristal acetate. They contain not less than 90.0% and not more than 110.0% of the labelled amount of Ulipristal acetate (C$_{30}$H$_{37}$N$_{2}$O$_{4}$).

Identity tests

- Either tests A and B or tests A and C may be applied.

A. Carry out as described under 1.6 Spectrophotometry in the visible and ultraviolet regions. Use the solution (1) as prepared for “Assay”. Dilute 2.0 mL of solution (1) to 20.0 mL with mobile phase. The absorption spectrum of this solution, when observed between 230 nm and 400 nm, exhibits maxima at about 262 nm and 302 nm.

Alternatively, in combination with identity test B, where a diode-array detector is available, record the UV spectrum of the principal peak in the chromatograms with a diode array detector in the range of 230 nm to 400 nm. The UV spectrum of the principal peak in the chromatogram obtained with solution (1) corresponds...
to the UV spectrum of the peak due to ulipristal acetate in the chromatogram obtained with solution (2).

B. Carry out the test as described under 1.14.4 High-performance liquid chromatography using the conditions given under “Assay”. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to ulipristal acetate in the chromatogram obtained with solution (2).

C. Carry out test C.1 or where UV detection is not available, test C.2.

C.1 Carry out as described under 1.14.1 Thin layer chromatography using silica gel R6 as the coating substance and a freshly prepared mixture of 2 volumes of ethyl acetate R and 8 volumes of dichloromethane R as the mobile phase. Apply separately to the plate 2 µL of each of the following two solutions: For solution (A), transfer a quantity of powdered tablets, nominally containing 60 mg of ulipristal acetate, into a 10 mL volumetric flask. Dilute to volume using dehydrated ethanol R. Stir or shake for 15 minutes. For solution (2), use a solution containing 6 mg of ulipristal acetate RS per mL of dehydrated ethanol R. After removing the plate from the chromatographic chamber, allow it to dry in air. Then heat the plate for 5 minutes in an oven at 100 °C. Examine the chromatogram under ultraviolet light (254 nm).

The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to ulipristal acetate in the chromatogram obtained with solution (B).

C.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R5 as the coating substance and the conditions as described above under test C.1. Spray the plate with a 100 g/L solution
of phosphomolybdic acid R in dehydrated ethanol R. Heat the plate in an
oven at 100 °C until spots appear (for about 5 minutes). Examine the
chromatogram under visible light. The principal spot in the
chromatogram obtained with solution (A) corresponds in position,
appearance and intensity with the spot due to Ulipristal acetate in the
chromatogram obtained with solution (B).

**Dissolution.** Carry out the test as described under *5.5 Dissolution test for oral dosage forms*, using as the dissolution medium 900 mL of hydrochloric acid (0.1 mol/L) VS. Rotate the paddle at 50 revolutions per minute. At 15 minutes, withdraw a sample of 10 mL of the medium through an in-line filter and allow the filtered sample to cool to room temperature.

Measure the absorbance as described under *1.6 Spectrophotometry in the visible and ultraviolet regions* in a cuvette with an optical pathlength of 10 mm at about 309 nm, using the dissolution medium as the blank. At the same time and under the same conditions, measure the absorbance of a solution of ulipristal acetate RS with a suitable concentration in dissolution medium, using dissolution medium as a blank. Dilute if necessary.

For each of the tablets tested, calculate the total amount of ulipristal acetate (C$_{30}$H$_{37}$NO$_4$) in the medium from the absorbances obtained. Evaluate the results as described under *5.5 Dissolution test for solid dosage forms*, Acceptance criteria. The amount of ulipristal acetate released is not less than 80% (Q) of the amount declared on the label.

*[Note from the Secretariat. It is intended to determine the absorptivity value of Ulipristal acetate in the dissolution medium and to use this value for the calculation of the test result.]*

**Related substances.** Perform the test using low-actinic glassware. Carry out the test as described under *1.14.4 High-performance liquid chromatography*, using the conditions given below under “Assay”, with the following modifications.
Prepare the following solution in mobile phase: Use solution (1) as described under “Assay”. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3), dilute 2.0 mL of solution (2) to 20.0 mL. For solution (4), prepare a solution containing 0.3 mg/mL ulipristal acetate RS and 0.015 mg/mL ulipristal acetate impurity A RS.

As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm.

Inject alternately 10 µL each of solutions (1), (2), (3) and (4).

The impurities are eluted, if present, at the following relative retentions with reference to ulipristal acetate (retention time about 9.1 minutes): impurity B about 0.66; impurity C about 0.87 and impurity A about 1.05.

The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to ulipristal acetate and impurity A is at least 1.3. Also, the test is not valid unless, in the chromatogram obtained with solution (3), the peak due to ulipristal acetate is obtained with a signal-to-noise ratio of at least 10.

In the chromatogram obtained with solution (1):

- the area of any peak corresponding to impurity B is not greater than 3 times the area of the peak due to ulipristal acetate in the chromatogram obtained with solution (2) (3.0 %);
- the area of any peak corresponding to impurity C is not greater than 0.5 times the area of the peak due to ulipristal acetate in the chromatogram obtained with solution (2) (0.5 %);
- the area of any other impurity peak is not greater than 0.2 times the area of the peak due to ulipristal acetate in the chromatogram obtained with solution (2) (0.2 %).
- The sum of the areas of all impurity peaks is not greater than 3.5 times the area of the peak due to ulipristal acetate in the chromatogram obtained with
solution (2) (3.5%). Disregard all peaks with an area of less than the area of the peak due to ulipristal acetate in the chromatogram obtained with solution (3) (0.1%).

**Assay.**

- Either test A or test B may be applied.

A. Perform the test using low-actinic glassware. Carry out the test as described under 1.14.4 *High-performance liquid chromatography*, using a stainless steel column (4.6 mm x 25 cm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 µm).¹

Prepare a phosphate buffer by dissolving 4.76 g of potassium dihydrogen phosphate R in 1000 mL of water R. Adjust the pH to 7.0 with triethylamine R. As the mobile phase, use a mixture of 40 volumes of acetonitrile R, 15 volumes of tetrahydrofuran R and 45 volumes of the phosphate buffer.

Operate with a flow rate of 1.0 mL per minute.

As a detector, use an ultraviolet spectrophotometer set at a wavelength of 305 nm.

Prepare the following solutions in mobile phase: For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, nominally containing 30.0 mg of ulipristal acetate, to a 100 mL volumetric flask. Add 40 mL and sonicate for 5 minutes, cool to room temperature, make up to volume and filter. For solution (2), dissolve 30.0 mg of ulipristal acetate RS in 20 mL using sonication, dilute to 100.0 mL and filter.

---

¹ A Hichrom Apex ODS column was found suitable.
Inject alternately 10 µL each of solutions (1) and (2) and record the chromatogram for 2.5 times the retention time of ulipristal acetate.

Measure the areas of the peaks corresponding to ulipristal acetate obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of ulipristal acetate (C_{30}H_{37}NO_{4}) in the tablets, using the declared content of C_{30}H_{37}NO_{4} in ulipristal acetate RS.

B. Perform the test using low-actinic glassware. Weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, nominally containing 30.0 mg of Ulipristal acetate, to a 100 mL volumetric flask. Add 40 mL of methanol R and sonicate for 5 minutes. Cool to room temperature and make up to volume. Dilute 5.0 mL of this solution to 50.0 mL with the same solvent.

Measure the absorbance as described under 1.6 *Spectrophotometry in the visible and ultraviolet regions* of the resulting solution in a cuvette with an optical pathlength of 10 mm at the maximum of about 302 nm.

Calculate the percentage content of C_{30}H_{37}NO_{4} in the tablets, using the absorptivity value of 48.5 for ulipristal acetate (A_{1\% cm} = 484).

**Impurities**

The impurities limited by the requirements of this monograph include those listed in the monograph on Ulipristal acetate.

**Reference substances to be established**

*Ulipristal acetate impurity A RS*

- *International Chemical Reference Substance to be established.*
Ulipristal acetate RS

- International Chemical Reference Substance to be established.